PDS Biotechnology has appointed John Dawson, Deborah Ramsdell, and Bruce Wendel to its board as it advances PDS0301 toward a Phase 3 trial in metastatic colorectal cancer. The move aims to bolster corporate development and partnership strategy.
PDS Biotechnology has appointed John Dawson, Deborah Ramsdell, and Bruce Wendel to its board as it advances PDS0301 toward a Phase 3 trial in metastatic colorectal cancer. The move aims to bolster corporate development and partnership strategy.